Bioanalytical Strategies for New Modalities - Part 1

Moderator(s)

• BR

  Brad Roadcap

  Director
  Merck & Co., Inc.
  West Point, Pennsylvania

Presentations:

• 8:05 AM – 8:35 AM CST

  Development of siRNA Therapeutics: What Data are Needed for PK and ADA Assessment
  

  Speaker: An Zhao, PhD – Regeneron Pharmaceuticals, Inc.
• 8:35 AM – 9:05 AM CST

  Investigation of Antibody Drug Conjugate’s Fast Clearance: Assay or Biology?
  

  Speaker: Cynthia M. Chavez-Eng, PhD – Merck & Co., Inc.
• 9:05 AM – 9:35 AM CST

  ADCs – LBA vs Hybrid: Hybrid LC-MS/MS Technology vs LBA for the Bioanalysis of Antibody-Drug-Conjugates Examples and Case Studies for Hybrid
  

  Speaker: Dawn Dufield, PhD – KCAS Bio
• 9:35 AM – 10:05 AM CST

  Impact of Soluble Target on Clinical ADA Assessment
  

  Speaker: Karen Liao, MD – Merck & Co., Inc.